AbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors?

AbbVie raised its quarterly dividend 5.5% to $1.73 per share ($6.92 annualized), but its 28.64% year-to-date share-price gain has reduced the yield to about 2.4%. The payout is about 49.5% of midpoint 2026 adjusted EPS guidance, with free cash flow yield of 3.56%; Skyrizi and Rinvoq together generated $8.03 billion in second-quarter sales, while Humira fell 35.9%. The pending $10.9 billion Apogee acquisition is expected to reduce 2026 EPS by $0.14 and add borrowing; management targets net leverage of 2x within two to three years after closing.

Analysis

The dividend thesis is better framed as growth durability than current income: after the rally, the yield offers limited cushion if execution disappoints. Adjusted-EPS coverage looks adequate, but it is not a substitute for checking cash conversion and acquisition-related cash needs; the reported FCF yield is not itself a payout-coverage ratio. The key balance-sheet risk is whether AbbVie can fund Apogee integration and reduce leverage without slowing capital returns.

The growth engine also raises concentration risk. Skyrizi and Rinvoq must keep offsetting Humira erosion while Imbruvica weakens; a modest shortfall in the growth drugs could matter more to the equity multiple than the stated near-term EPS dilution from Apogee. Management’s patent and market-share claims are not guarantees against competing therapies or future pricing pressure. Over 1–3 months, watch deal close/integration updates, cash-flow conversion and leverage commentary; over 6–18 months, the test is sustained growth in the immunology franchise and progress toward the leverage target.

Contrarian angle: the headline dividend metrics may understate risk, but the deal’s stated EPS drag alone does not establish a dividend threat. The more useful relative distinction is AbbVie’s post-Humira growth transition versus Bristol Myers Squibb’s ongoing product erosion—not a blanket conclusion that AbbVie is cheap after a sharp rerating. Falsifiers for the constructive view are slowing Skyrizi/Rinvoq growth, weaker free cash flow, or leverage failing to trend down; sustained execution would support dividend growth, though not necessarily a higher starting yield.

Key Decisions for Investors

• Do not chase ABBV solely for income at the post-rally yield. For existing holders, retain the dividend-growth exposure but reassess after the next results; verify operating cash flow, capital spending and acquisition-related cash uses rather than relying on adjusted-EPS payout alone.
• Consider a modest, dollar-neutral ABBV-long/BMY-short relative-value position only if comfortable with pharma-specific risk: the thesis is more durable growth at AbbVie versus continued erosion at Bristol Myers Squibb, not an absolute valuation call. Reduce or exit if AbbVie’s immunology growth decelerates materially or BMY demonstrates durable growth-portfolio offsets; compare valuation and estimate revisions before entry.
• Treat Apogee close and deleveraging as watch items, not a standalone trade: check financing, integration costs and quarterly net leverage. A failure to show a declining leverage trajectory over coming quarters would weaken the dividend-growth thesis and could prompt a lower multiple.
• For new income capital, compare ABBV’s yield and dividend-growth profile with JNJ and other income alternatives rather than treating its Aristocrat label as evidence of equivalent history; AbbVie’s own dividend record is shorter than the inherited index history suggests.